These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 22713338)
21. In vitro sensitivity of Acinetobacter baumannii and Pseudomonas aeruginosa to carbapenems among intensive care unit patients. Guzek A; Korzeniewski K; Nitsch-Osuch A; Rybicki Z; Prokop E Adv Exp Med Biol; 2013; 788():109-16. PubMed ID: 23835967 [TBL] [Abstract][Full Text] [Related]
23. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. Castanheira M; Jones RN; Livermore DM Diagn Microbiol Infect Dis; 2009 Apr; 63(4):426-33. PubMed ID: 19249180 [TBL] [Abstract][Full Text] [Related]
24. Concentration-resistance relationships with Pseudomonas aeruginosa exposed to doripenem and ciprofloxacin in an in vitro model. Zinner SH; Gilbert D; Greer K; Portnoy YA; Firsov AA J Antimicrob Chemother; 2013 Apr; 68(4):881-7. PubMed ID: 23175594 [TBL] [Abstract][Full Text] [Related]
25. Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Kuti JL; Florea NR; Nightingale CH; Nicolau DP Pharmacotherapy; 2004 Jan; 24(1):8-15. PubMed ID: 14740783 [TBL] [Abstract][Full Text] [Related]
26. Pharmacodynamics of razupenem (PZ601) studied in an in vitro pharmacokinetic model of infection. MacGowan AP; Noel A; Tomaselli S; Elliott H; Bowker K Antimicrob Agents Chemother; 2011 Apr; 55(4):1436-42. PubMed ID: 21263054 [TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamics of minocycline against Acinetobacter baumannii studied in a pharmacokinetic model of infection. Alfouzan WA; Noel AR; Bowker KE; Attwood MLG; Tomaselli SG; MacGowan AP Int J Antimicrob Agents; 2017 Dec; 50(6):715-717. PubMed ID: 28705678 [TBL] [Abstract][Full Text] [Related]
28. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection. MacGowan AP; Noel AR; Tomaselli SG; Nicholls D; Bowker KE Antimicrob Agents Chemother; 2016 Jan; 60(1):515-21. PubMed ID: 26552975 [TBL] [Abstract][Full Text] [Related]
29. Nakamura R; Ito-Horiyama T; Takemura M; Toba S; Matsumoto S; Ikehara T; Tsuji M; Sato T; Yamano Y Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262762 [TBL] [Abstract][Full Text] [Related]
30. Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection. MacGowan AP; Noel AR; Tomaselli S; Elliott HC; Bowker KE Antimicrob Agents Chemother; 2011 Feb; 55(2):867-73. PubMed ID: 21078943 [TBL] [Abstract][Full Text] [Related]
31. Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection. MacGowan AP; Bowker KE; Noel AR Antimicrob Agents Chemother; 2008 Apr; 52(4):1401-6. PubMed ID: 18227179 [TBL] [Abstract][Full Text] [Related]
33. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09. Davies TA; Marie Queenan A; Morrow BJ; Shang W; Amsler K; He W; Lynch AS; Pillar C; Flamm RK J Antimicrob Chemother; 2011 Oct; 66(10):2298-307. PubMed ID: 21775338 [TBL] [Abstract][Full Text] [Related]
34. Antimicrobial resistance surveillance of doripenem in China. Li Y; Lv Y; Xue F; Zheng B; Liu J; Zhang J J Antibiot (Tokyo); 2015 Aug; 68(8):496-500. PubMed ID: 25850342 [TBL] [Abstract][Full Text] [Related]
35. Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region. Kiratisin P; Keel RA; Nicolau DP Int J Antimicrob Agents; 2013 Jan; 41(1):47-51. PubMed ID: 23127484 [TBL] [Abstract][Full Text] [Related]
36. Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii. Tsuji BT; Landersdorfer CB; Lenhard JR; Cheah SE; Thamlikitkul V; Rao GG; Holden PN; Forrest A; Bulitta JB; Nation RL; Li J Antimicrob Agents Chemother; 2016 Jul; 60(7):3913-20. PubMed ID: 27067330 [TBL] [Abstract][Full Text] [Related]
37. Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance. Ly NS; Bulitta JB; Rao GG; Landersdorfer CB; Holden PN; Forrest A; Bergen PJ; Nation RL; Li J; Tsuji BT J Antimicrob Chemother; 2015 May; 70(5):1434-42. PubMed ID: 25712313 [TBL] [Abstract][Full Text] [Related]
38. Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients. Kays MB; Fleming MR; Cheatham SC; Chung EK; Juenke JM Ann Pharmacother; 2014 Feb; 48(2):178-86. PubMed ID: 24259653 [TBL] [Abstract][Full Text] [Related]
39. Pharmacodynamics of Meropenem against Acinetobacter baumannii in a Neutropenic Mouse Thigh Infection Model. Sabet M; Tarazi Z; Griffith DC Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988101 [No Abstract] [Full Text] [Related]
40. Comparative in vitro activity of carbapenems against clinical isolates of Acinetobacter baumannii. Douraghi M; Ghalavand Z; Nateghi Rostami M; Zeraati H; Aliramezani A; Rahbar M; Mohammadzadeh M; Ghourchian S; Boroumand MA; Abdollahi A J Appl Microbiol; 2016 Aug; 121(2):401-7. PubMed ID: 27171885 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]